T he incidence of inflammatory bowel disease (IBD) had been on the rise in the 1950s through the 1990s in the developed world and over the past 25 years in the developing world. 1 Any potential etiologic exposure should be something that has become increasingly prevalent during this period. There is an increasing speculation that gut microbiome dysbiosis predisposes to the development of the aberrant intestinal immune response in both Crohn's disease and ulcerative colitis, the 2 main forms of IBD. 2 The exact nature of the dysbiosis and timing of its evolution in persons with IBD is a subject of the ongoing study. 3 The human gut microbiome is thought to evolve from birth until around age 1 year when its composition converges on what will approximate its adult state. [4] [5] [6] Therefore, exposures which influence the evolution of the gut microbiome early in life may increase the risk of subsequently developing IBD. One event that can impact on the developing neonatal gut microbiome is the mode of delivery because birth by cesarean section compared with vaginal delivery leads to considerable differences in the neonate's gut microbiota. 7, 8 Cesarean section delivery rates have become increasingly prevalent in the last several decades, both in developed and developing nations. 9, 10 However, we recently reported that being born by cesarean section had no impact on whether offspring ultimately were diagnosed with IBD or not. 11 Antibiotics ingestion can alter the gut microbiome, and their use has dramatically risen worldwide over the past 50 years which coincides with the rise in IBD. In a previous study, we reported that children diagnosed with IBD were more likely to have received antibiotics in the first year of life than matched population-based controls. 12 Others have also shown antibiotic use antedate the onset of IBD in both children and adults. 13 Although it has been long assumed that infants are born with a sterile gut, only acquiring their gut flora during the birth process, evidence has emerged suggesting that microbes may actually translocate from the mother's gastrointestinal tract, reach the developing fetus hematogenously, and seed the fetal gastrointestinal tract. 14 Hence, events affecting the composition of the maternal gastrointestinal microbiome (such as diet or drug ingestion) may impact on the developing fetal gastrointestinal microbiome. 15 This has been postulated for the development of necrotizing enterocolitis, and similarly could be considered relevant for children who ultimately develop IBD. 14, 16 Our group has recently reported that pregnant mice that are given antibiotics induce changes in the offspring's intestinal bacterial colonization, which seems to increase offspring susceptibility to developing colonic inflammation in a murine model of colitis. 17 Other circumstantial evidence suggests that bacteria can be transmitted from the mother to the fetus. 18 Concern has been expressed for the overuse of antibiotics in pregnancy in terms of their unknown effects on the developing fetus. 19, 20 Therefore, we sought to determine whether maternal antenatal or perinatal antibiotic use impacts on the development of IBD in offspring.
METHODS

Study Population
The University of Manitoba IBD Epidemiology Database (UMIBDED) contains records of all Manitobans diagnosed with IBD between 1984 and March 2010 extracted from the administrative data of Manitoba Health, the single provincial health insurance provider using a well-validated case-finding algorithm. 21 Each individual with IBD is matched to 10 non-IBD controls by age, sex, and area of residence. Through unique 9-digit personal health identification numbers, all health system contacts in the province, including outpatient visits and hospitalizations and the diagnoses and providers associated with those contacts, can be tracked. Starting in 1970, 6-digit family health registration numbers, shared by a mother and all of her offspring, have been used in Manitoba and allow for the accurate linkage of the health care utilization profiles of mothers with their children. 22 This study included all persons with IBD in the UMIBDED, their nonaffected siblings, and their matched controls who were born from 1970 and onward. Maternal health records including dates and modes of delivery were noted.
Identification of Antepartum and Peripartum Infection
We specified all maternal infections highly likely to have warranted antibiotic prescription in the 9 months before delivery in both inpatient and outpatient files and also within the peripartum period in inpatient data files. See Table 1 for a list of included infections. Infections unlikely to lead to antibiotic prescription like upper respiratory infections, influenza, and colds were excluded.
Antibiotic Use
Beginning in 1995, all outpatient prescription medications dispensed to Manitobans registered in the Manitoba Health administrative health records are recorded in the Drug Program Information Network database. Hence, for persons with IBD born from 1996 to 2010, we could determine whether mothers were dispensed antibiotics in the antepartum period. Therefore, for all children with IBD born after 1996, we queried the drug dispensation history of their mothers for all instances of antibiotic dispensation (ATC code J01: antibacterials for systemic use) in the 9 months before delivery. Antibiotics given in the peripartum as inpatient prescriptions are not captured in the Drug Program Information Network and could not be identified.
Outcomes and Analysis
To assess for socioeconomic status, we used the median household income quintile for the area of residence at the time of birth identified by the subjects' 6-digit postal code at the time of birth. 23 We differentiated urban from rural income quintiles, generating 10 categories of income to assess. Mothers of IBD cases and mothers of controls were compared for age at delivery, length of gestation, comorbidity scores (using the Johns Hopkins ACG Case-Mix System 24 ), and for comorbidity with common chronic immune diseases. We used the Johns Hopkins ACG Case-Mix System to assess comorbidity instead of the Charlson Comorbidity Index because the former includes assessment of both inpatient and outpatient visits, whereas the Charlson was created to assess inpatient comorbidity. Prevalence rates of antepartum infections within 9 months before delivery, within 30 days before delivery, and peripartum infections were determined on a per-pregnancy basis for mothers of IBD cases and their unaffected siblings and mothers of controls. Comparisons between the groups overall and within specific strata (sex, by age at diagnosis [,11 years, 11-20 years, and .20 years], income quintile, and urban/rural) were assessed using Fisher's exact test. Conditional logistic regression models estimated the odds of developing IBD among cases whose mothers had an antepartum or peripartum infection, compared with unaffected controls or unaffected siblings, and adjusting for urban versus rural residence, socioeconomic status (income quintiles), age, and sex, and odds ratios (ORs) with 95% confidence intervals (CIs) are reported. We also pursued a multivariate model assessing whether maternal antenatal or perinatal infections impacted on age at diagnosis in persons with IBD. We included the sex of the affected individual, geographic residence at the time of birth (urban or rural), and socioeconomic status.
This study was approved by the University of Manitoba Health Research Ethics Board, the Manitoba Health Information Privacy Committee, and the Manitoba Centre for Health Policy Review Committee.
RESULTS
There were 2487 persons with IBD in the UMIBDED born after 1970. Of these, 1758 were born in Manitoba, of whom 1671 were linkable to mothers (Crohn's disease, n ¼ 973, and ulcerative colitis, n ¼ 698). Of the 16,710 potential controls, 10,488 were born in the province and linkable to their mothers. Individuals who developed IBD were more likely to be urban residents and reside in higher income quintiles than the controls at the time of their birth ( Table 2) .
A comparison of mothers of offspring with IBD and mothers of controls for maternal age at delivery, gestation length, comorbidity score, and comorbidity with common chronic immune diseases is presented in Table 3 . There were no significant differences between the 2 cohorts of mothers on those parameters. Mothers of offspring with IBD were no more likely than mothers of controls to have had an infection within nine months before delivery, within 30 days before delivery, or in the peripartum period (Table 4) . In a multivariate conditional logistic regression analysis, controlling for urban residence, income quintile, and mode of delivery, none of antenatal infection within 9 months of delivery (OR ¼ 0.96, 95% CI 0.84-1.09), antenatal infection within 30 days of delivery (OR ¼ 0.97, 95% CI 0.87-1.14), or peripartum infection (OR ¼ 0.86, 95% CI 0.68-1.09) was associated with subsequent development of IBD.
There were 1744 unaffected siblings from 1615 families identified. The current mean age of the IBD cohort is 33.41 6 6.99 years and of the siblings is 30.74 6 8.64 years (P , 0.001). This reflects that those affected with IBD were more likely than their unaffected siblings to be higher in the birth order. The pregnancies of mothers of offspring diagnosed with IBD were no more likely to have been affected by an antenatal infection within 30 days of delivery or in the perinatal period than the pregnancies of the unaffected siblings of the IBD cases (Table 5) . There were 11 persons with IBD born after April 1, 1996, in whom maternal antibiotic exposure could be ascertained, along with 274 controls and 123 siblings. We did not detect any difference in the prevalence of maternal antibiotic exposure during the pregnancies of IBD cases (32.3%), matched controls (36.5%, P ¼ 0.75), and their unaffected siblings (30.1%, P ¼ 0.07).
In assessing age at diagnosis among those with IBD as to whether or not their mothers experienced antenatal or perinatal infections, we found a significantly younger age at diagnosis among those born to mothers who had perinatal infection but not among those whose mothers had antenatal infections (Table 6) .
DISCUSSION
These population-based analyses were unable to detect any significant difference in the rates of antenatal infections, perinatal infections, or maternal antibiotic exposure between IBD cases and their matched controls or unaffected siblings. These findings support the notion that the use of antibiotics by mothers at any time during pregnancy or in the peripartum does not increase the risk for developing IBD, despite any purported effects on the gut microbiome of the mother and the developing neonate.
We sought to assess the relationship between maternal infections or antibiotic exposure and the subsequent risk of IBD in offspring because of multiple lines of evidence suggesting that alteration of the microbial milieu during pregnancy can have deleterious effects on children born from that pregnancy. Changes in vaginal bacterial diversity and composition occur over the course of gestation. 18, 25, 26 There is also evidence that the maternal gastrointestinal microbiome diversity decreases over the course of pregnancy. 27 The gastrointestinal microbiome of the newborn is dominated by maternal vaginal and gastrointestinal tract microbiota, if birth occurs vaginally, and by maternal skin microorganisms, if birth occurs by cesarean section. 14 Recently, we reported that birth by cesarean section was no more common among persons with IBD than unaffected controls in the general population or unaffected siblings. 11 Hence, with time and closeness to the mother, especially with breastfeeding, a typical gastrointestinal tract flora emerges in the developing child.
Several studies have shown that antibiotics before, during, and after birth disrupt the natural microbiome assembly. 18, [28] [29] [30] [31] [32] Intrapartum antibiotic use has been associated with decreased bacterial diversity of the neonate's first stool 28, 33 and lower abundance of lactobacilli and bifidobacteria in the neonatal gut. [28] [29] [30] [31] [32] In one study of healthy mothers and singleton vaginal deliveries, vertical transmission of lactobacillus in mothers receiving intrapartum antibiotics was impaired. 29 Antibiotics can effect changes in both gastrointestinal microbiome and immune response. 34 Changes in the gastrointestinal microbiome which occur subsequent to antibiotic use can persist for months and in some instances even years. [35] [36] [37] Hence, maternal use of antibiotics even early in pregnancy can have long-lasting effects. Epidemiologic studies have demonstrated a correlation between the use of antibiotics in pregnancy and an increased risk of childhood obesity 38 and asthma. 39 Regardless of the potential impact of maternal use of antibiotics on the maternal gastrointestinal and vaginal microbiome and secondarily on fetal and neonatal gastrointestinal microbiome, our current study suggests that this does not seem to impact on the rates of development of IBD. In the era before molecular characterization of microbes, a "critical" stage of gut colonization was considered to be after birth and then after weaning. 40 Although the birth period marks the establishment of microbial communities in different organ systems, other events during the first year of life may be more important. Hence, antenatal or perinatal use of antibiotics by the mother, even if it changes the maternal gastrointestinal microbiome (and other ecological niches like skin microbiome), either does not sufficiently impact on the neonatal microbiome to facilitate IBD development or alternatively these changes and possible risk for IBD are overcome as the maternal microbiome normalizes with the passage of time from the antibiotic use. Further changes to the infant's developing microbiome within the first years of life induced by diet, breastfeeding, or antibiotic use by the child may predispose to the eventual development of IBD. As reviewed elsewhere, 40 even the importance of breast milk to the developing infant may be overshadowed in terms of the gut microbiome and its metabolites by the timing and nature of food introduction. Hence, more study on events in the first year life, especially diet, may uncover more clues to the development of IBD.
Even though persons with IBD were no more likely than controls to have been born to mothers who experienced a peripartum infection, among those with IBD, if their mothers had a peripartum infecton likely to require an antibiotic, their age at diagnosis of IBD was significantly younger than those whose mothers did not have a peripartum infection requiring antibiotics (Table 6 ). This finding may suggest that in persons who were otherwise destined to present with IBD, if there are other factors that predispose to IBD development, the use of antibiotics peripartum by mothers (and by inference changes in microbiome that may in turn impact on the neonate's gut microbiome) may impact on the time to progression of IBD. Hence, overall, we did not find that perinatal infections increased the risk of ultimately developing IBD compared with controls, but those who did develop IBD developed it at a significantly younger age if they were exposed to peripartum antibiotics.
Our study has a large sample size of persons with IBD and is controlled for potential confounders such as sex, urban versus rural residence, and socioeconomic status. However, there are limitations to our study. Mothers of all persons with IBD could not be identified although the 5% missing cases for our study are not likely to impact on the outcomes because the comparison of maternal infections between cases and controls was so similar. In our comparison of persons with IBD and their unaffected siblings, in considering whether the sibling cohort had sufficient years to present with IBD, they were on average 30.7 6 8.64 years. Hence, some may still yet present with IBD. However, even if some of the sibling cohort present as adults with IBD, it is unlikely to change our results. It is not surprising that on average, the persons with IBD were older than their unaffected siblings, as the literature suggests that within a family those higher in the birth order are more likely to be affected with IBD than younger siblings. 41, 42 Furthermore, we are using maternal infections as a proxy for antibiotic use. However, if we erroneously chose infections that were not always treated by antibiotics or excluded infections that may have been treated by antibiotics, the same biases would have existed for cases and controls. Furthermore, we were addressing predominately bacterial infections, and perhaps, maternal infections with nonbacterial pathogens such as viruses, parasites, and fungi may be important in altering the neonatal microbiome and risk for IBD. While we have accounted for important potential confounders on maternal microbiome like urban versus rural residence socioeconomic status and mode of delivery, other maternal factors that may confer a risk on the development of IBD were not specified. These include maternal smoking and diet. We also did not have information on important childhood factors such as timing and nature of diet introduction, childhood infections, and childhood medication use.
In summary, events during the antepartum or immediate postpartum period, such as maternal use of antibiotics and maternal infections, which could shape the developing neonate gut microbiome do not seem to impact on the ultimate development of IBD in this population-based sample. An implication of our findings is that events happening later in childhood, which impact on the gut microbiome, may be more crucial in enhancing the risk for the 
